COA Applauds CMS' Decision on CAR T-Cell Therapy
Following CMS’ decision to make chimeric antigen receptor (CAR) T-cell therapy available to Medicare beneficiaries nationwide, including in the community oncology setting, the Community Oncology Alliance (COA) applauded the decision.
Following CMS’ decision to make chimeric antigen receptor (CAR) T-cell therapy available to Medicare beneficiaries nationwide, including in the community oncology setting, the Community Oncology Alliance (COA) applauded the decision. According to COA, the agency listened to the feedback of community practices by ensuring that CAR T-cell therapy is covered outside of the hospital setting.
COA is also pleased that by protecting Medicare beneficiaries, the agency has streamlined the reporting requirements and aligned requirements between CMS and the FDA, which will reduce burden for providers, Medicare, and patients.
Read the full press release.
